RxDoctor Payments Data

Jaipal Makhija, MD

Internal Medicine · Augusta, GANPI 1720419914

Payments from drug & device makers

$515in general payments, 2019–2025

Across 21 payments — averaging $24.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$141
  • Novartis$67
  • Merck$62
  • AbbVie$53
  • Solventum Corporation$44
  • Johnson & Johnson$44
  • plus $104 from 6 others

What the payments were for

  • Food & beverage$515100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$515 in reported general payments places this provider in the 55th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$134,744
Medicare patients
444
Services billed
1,407

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban26$13,363
FarxigaDapagliflozin Propanediol18$8,082
Midodrine Hcl17$868
Atorvastatin Calcium59$571
Losartan Potassium50$294
Metoprolol Succinate48$288
Bumetanide21$286
Pantoprazole Sodium52$230
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav26$150
Amiodarone Hcl21$145
ClopidogrelClopidogrel Bisulfate22$113
Amlodipine Besylate36$91
Isosorbide Mononitrate ErIsosorbide Mononitrate12$75
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen19$68
Prednisone30$65

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$16$13,36326 claims
AstraZenecaFarxiga$141$8,08218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →